One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.
Gabriela Grimaldi, Aude Ambresin, Isabel B Pfister, Christin Schild, Christina Plasencia, Katja Hatz, Richard Stillenmunkes, Marion R Munk, Arianna Paris, Moreno Menghini, Dmitri Artemiev, Andreas Ebneter, Jennifer Cattaneo, Eva C de Oliveira Figueiredo, Chiara M Eandi, Jacqueline Fröhlich, Nicolas Feltgen, Tahm Spitznagel, Gábor Márk Somfai, Mariano Cozzi, Sandrine Zweifel, Andreas Weinberger, Justus G Garweg
{"title":"One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.","authors":"Gabriela Grimaldi, Aude Ambresin, Isabel B Pfister, Christin Schild, Christina Plasencia, Katja Hatz, Richard Stillenmunkes, Marion R Munk, Arianna Paris, Moreno Menghini, Dmitri Artemiev, Andreas Ebneter, Jennifer Cattaneo, Eva C de Oliveira Figueiredo, Chiara M Eandi, Jacqueline Fröhlich, Nicolas Feltgen, Tahm Spitznagel, Gábor Márk Somfai, Mariano Cozzi, Sandrine Zweifel, Andreas Weinberger, Justus G Garweg","doi":"10.1016/j.oret.2025.03.015","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To report the efficacy and safety of switching to faricimab in a real-world, Swiss cohort of patients with pretreated neovascular age-related macular degeneration (nAMD).</p><p><strong>Design: </strong>Retrospective, multicenter, longitudinal observational study conducted at 11 centers of the Swiss Retina Research Network.</p><p><strong>Subjects: </strong>We included 353 eyes of 325 patients who were switched to intravitreal faricimab after prior anti-VEGF therapy and followed for a minimum of 12 months between May 1, 2022, and October 30, 2024.</p><p><strong>Methods: </strong>Demographic characteristics, baseline functional and OCT findings, treatment history, and outcomes at 12 months after switch to faricimab were extracted from the patients' electronic case report forms.</p><p><strong>Main outcome measures: </strong>Change in best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of retinal fluid (RF) and pigment epithelial detachment, treatment intervals, and safety signals.</p><p><strong>Results: </strong>Twelve months after switch, mean BCVA remained unchanged, whereas mean CST decreased from 315.3 to 263.9 μm (P < 0.01). Fast drying (absence of RF) after 1 faricimab injection was observed in 134 eyes (38%) and correlated positively with the treatment interval at 12 months (r(301) = 0.24; P < 0.01). After 12 months, 169 (47.9%) eyes demonstrated the absence of RF compared with 10.2% at switch. Mean treatment interval increased from 5.8 ± 2.5 weeks at switch to 8.3 ± 4.2 weeks at 12 months, and extended treatment intervals (≥12 week) were achieved in 20% of patients. Mild intraocular inflammation was reported in 1.7% of cases.</p><p><strong>Conclusions: </strong>Switching to faricimab in pretreated nAMD led to sustained anatomic improvements and stabilization of BCVA, with a substantial reduction in RF compared with baseline. Our results suggest the potential benefits of this switching strategy based on real-world data.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oret.2025.03.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To report the efficacy and safety of switching to faricimab in a real-world, Swiss cohort of patients with pretreated neovascular age-related macular degeneration (nAMD).
Design: Retrospective, multicenter, longitudinal observational study conducted at 11 centers of the Swiss Retina Research Network.
Subjects: We included 353 eyes of 325 patients who were switched to intravitreal faricimab after prior anti-VEGF therapy and followed for a minimum of 12 months between May 1, 2022, and October 30, 2024.
Methods: Demographic characteristics, baseline functional and OCT findings, treatment history, and outcomes at 12 months after switch to faricimab were extracted from the patients' electronic case report forms.
Main outcome measures: Change in best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of retinal fluid (RF) and pigment epithelial detachment, treatment intervals, and safety signals.
Results: Twelve months after switch, mean BCVA remained unchanged, whereas mean CST decreased from 315.3 to 263.9 μm (P < 0.01). Fast drying (absence of RF) after 1 faricimab injection was observed in 134 eyes (38%) and correlated positively with the treatment interval at 12 months (r(301) = 0.24; P < 0.01). After 12 months, 169 (47.9%) eyes demonstrated the absence of RF compared with 10.2% at switch. Mean treatment interval increased from 5.8 ± 2.5 weeks at switch to 8.3 ± 4.2 weeks at 12 months, and extended treatment intervals (≥12 week) were achieved in 20% of patients. Mild intraocular inflammation was reported in 1.7% of cases.
Conclusions: Switching to faricimab in pretreated nAMD led to sustained anatomic improvements and stabilization of BCVA, with a substantial reduction in RF compared with baseline. Our results suggest the potential benefits of this switching strategy based on real-world data.
Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
